icotinib

01/01/2020 - "Our primary purpose is to explore safety and efficacy of high-dose icotinib in comparison with routine-dose icotinib in patients with non-small cell lung cancer (NSCLC) harboring 21-L858R mutation. "
09/01/2013 - "Icotinib could be a new treatment option for pretreated patients with advanced non-small-cell lung cancer."
10/01/2023 - "This phase 3 trial compared the efficacy and safety of befotertinib with icotinib as a first-line treatment for patients with EGFR mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC). "
11/01/2016 - "This phase I study evaluated the maximum tolerated dose, dose-limiting toxicities, safety, pharmacokinetics, and efficacy of icotinib with a starting dose of 250 mg in pretreated, advanced non-small cell lung cancer patients. "
05/01/2014 - "Efficacy of Icotinib treatment in patients with stage IIIb/IV non-small cell lung cancer."

09/06/2020 - "Non-small cell lung adenocarcinoma with EGFR L858R/V834L was treated successfully with icotinib, and it may be a new medication treatment option."
01/01/2016 - "Icotinib monotherapy is effective and tolerable as first-line treatment for patients with advanced lung adenocarcinoma with EGFR-sensitive mutation."
01/01/2016 - "Icotinib was an effective and safe strategy to treat patients with BMs from lung adenocarcinoma."
01/01/2023 - "Two-year adjuvant icotinib was shown to significantly improve DFS and provide an OS benefit in EGFR-mutant, stage II-IIIA lung adenocarcinoma patients compared with 1-year treatment in this exploratory phase II study."
01/01/2023 - "Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)."

12/01/2022 - "This study suggests that CPRT is a viable option for patients with EGFR-sensitive mutations in NSCLC with limited multiple metastases during first-line icotinib treatment, which can significantly improve PFS with acceptable toxicities. "
07/01/2023 - "Two months after the treatment with icotinib, the choroidal metastases regressed to small lesions, and the visions were preserved to before. "
12/01/2022 - "EGFR-mutant NSCLC patients diagnosed with limited multiple metastases were treated with first-line icotinib. "
01/01/2021 - "The presence of liver and brain metastasis predicted unfavorable OS, while the presence of lung metastasis predicted favorable OS in first-line icotinib-treated patients with EGFR-mutated stage IV NSCLC."
01/26/2020 - "This is the first successful example of pulsatile icotinib for treating isolated CNS progression from EGFR mutation-positive NSCLC, providing a new alternative for the local treatment of CNS metastases."

06/01/2012 - "Our results suggest the possibility of icotinib as a new therapeutic agent of EGFR-mutated cancer cells, which has the potential to be used in the first-line treatment of EGFR-mutated NSCLC."
01/01/2018 - "Molecular mechanism study revealed that icotinib inhibited the phosphorylation of EGFR and PDL1 expression in cancer cells and activated apoptosis. "
05/01/2012 - "In vivo studies demonstrated that Icotinib exhibited potent dose-dependent antitumor effects in nude mice carrying a variety of human tumor-derived xenografts. "
12/01/2021 - "Accordingly, the anti-cancer effect of BBR plus icotinib was further confirmed in the NSCLC xenograft mouse models. "
12/01/2021 - "Moreover, xenograft mouse model was applied for assessing the anti-tumor activities of BBR and icotinib in combination. "

01/01/2022 - "The Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-Positive Patients Diagnosed With Lung Cancer (CHALLENGE) trial is a prospective, multicentered, open-label, single-arm phase 2 nonrandomized clinical trial conducted between July 1, 2017, and July 31, 2019. "
05/16/2018 - "In this study, we investigated the effectiveness of Icotinib in enhancing lung cancer cell radiosensitivity and have detailed its underlying molecular mechanism. "
06/11/2022 - "CQ effectively restored lung cancer cell sensitivity to icotinib in vitro and in vivo. "
01/01/2020 - "The response to icotinib in advanced non-small cell lung cancers (NSCLC) with EGFR uncommon mutation (EGFRum) is unclear. "
05/16/2018 - "In conclusion, our results reveal that Icotinib enhances radiosensitivity in lung cancers in vitro and in vivo and the mechanism of this may involve blocking the EGFR-AKT and MAPK-ERK pathways and limiting DNA repair."